Edesa Biotech is trading 6.5% down at $2.66 on October 14, 2026, alongside biotech weakness and a broader market retreat; the specific cause of the stock’s decline is unclear. - The XBI is down 2.01%, while investors react to hotter-than-expected core inflation. - No company announcement dated October 14 clearly explains the move; Edesa Biotech’s news page lists its $25 million offering announcement on August 19.